The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 ...

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one ...

XtalPi and DoveTree collaborate on a groundbreaking $6 billion drug discovery partnership, merging AI technology with ...

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

Chai Discovery secures $70 million to revolutionize AI-driven drug discovery, enhancing antibody design and accelerating breakthroughs in medicine.

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

HHS is winding down mRNA vaccine development, impacting contracts with major pharma companies and resulting in nearly $500 ...

The deal brings the FDA-approved neuroblastoma therapy Danyelza (naxitamab-gqgk) to SERB Pharmaceuticals and advances its ...

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years ...

The AI-driven collaboration will use Syntekabio’s DeepMatcher platform to identify new therapeutic targets for MetaVia’s ...

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...